OverviewSuggest Edit

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
TypePublic
Founded2008
HQSouth San Francisco, US
Websitecytomx.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)158(+16%)
Job Openings10
Revenue (FY, 2019)$57.5 M(-3%)
Share Price (Jun 2020)$8.2 (+2%)

Key People/Management at CytomX Therapeutics

Danielle Olander

Danielle Olander

Senior Vice President, Talent and Systems Development
Sean A. McCarthy

Sean A. McCarthy

President, Chief Executive Officer, and Chairman
Amy C. Peterson

Amy C. Peterson

Executive Vice President and Chief Development Officer
Sridhar Viswanathan

Sridhar Viswanathan

Senior Vice President, Process Sciences and Manufacturing Operations
Nick Galli

Nick Galli

Senior Vice President, Chief Business Officer
Charles S. Fuchs

Charles S. Fuchs

Director
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
151 Oyster Point Blvd #400
Show all (1)

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Revenue

CytomX Therapeutics's revenue was reported to be $57.49 m in FY, 2019
USD

Revenue (Q1, 2020)

49.6m

Net income (Q1, 2020)

12.2m

EBIT (Q1, 2020)

(2.8m)

Market capitalization (4-Jun-2020)

374.5m

Closing stock price (4-Jun-2020)

8.2

Cash (31-Mar-2020)

143.3m

EV

258.2m
CytomX Therapeutics's current market capitalization is $374.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.7m15.0m71.6m59.5m57.5m

Revenue growth, %

95%

General and administrative expense

12.6m19.9m25.6m33.5m36.8m

R&D expense

28.4m54.8m92.3m103.9m131.6m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

1.9m2.2m3.1m3.5m11.7m8.8m24.1m14.2m21.3m12.5m29.5m9.0m10.7m49.6m

General and administrative expense

4.1m5.0m4.6m5.0m5.7m6.0m6.2m7.4m9.0m8.1m9.7m9.4m8.5m9.6m

R&D expense

9.2m13.4m12.7m13.3m14.6m28.1m28.9m22.5m25.6m27.5m36.4m30.8m28.0m42.8m

Operating expense total

13.2m18.4m17.4m18.4m20.3m34.1m35.2m29.8m34.6m35.7m46.1m40.2m36.4m52.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

59.8m104.6m177.5m247.6m188.4m

Accounts Receivable

744.0k2.2m10.1m97.0k13.0k

Prepaid Expenses

4.4m9.3m7.2m

Inventories

2.3m3.9m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)(102.2m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m146.0k

Accounts Payable

2.9m1.8m(2.4m)261.0k(374.0k)

Cash From Operating Activities

(27.4m)(2.0m)170.4m(75.5m)(140.5m)
USDY, 2020

EV/EBIT

-92.5 x

EV/CFO

-5.2 x

Financial Leverage

6.3 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents (US)

13

Patents Pending

144

Phase I Trials Products

1
Show all operating metrics

CytomX Therapeutics Online and Social Media Presence

Embed Graph

CytomX Therapeutics News and Updates

CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update

Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting

- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types -

CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced…

CytomX Therapeutics Announces First Quarter 2019 Financial Results

Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT

CytomX Therapeutics Announces Full-Year 2018 Financial Results

Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST

CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announc…
Show more

CytomX Therapeutics Blogs

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

CytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations

Event Scheduled for Friday, May 29, 2020 at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif. , May 26, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

SOUTH SAN FRANCISCO, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today

CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

Company to Host a Conference Call Today, May 7, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational

CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference Content Import Tue, 05/05/2020 - 08:01 CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference May 5, 2020 at 8:00 AM EDT This rel…

CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program Content Import Wed, 04/29/2020 - 16:06 CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program …
Show more

CytomX Therapeutics Frequently Asked Questions

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Who are CytomX Therapeutics key executives?

    CytomX Therapeutics's key executives are Danielle Olander, Sean A. McCarthy and Amy C. Peterson.

  • How many employees does CytomX Therapeutics have?

    CytomX Therapeutics has 158 employees.

  • What is CytomX Therapeutics revenue?

    Latest CytomX Therapeutics annual revenue is $57.5 m.

  • What is CytomX Therapeutics revenue per employee?

    Latest CytomX Therapeutics revenue per employee is $363.9 k.

  • Who are CytomX Therapeutics competitors?

    Competitors of CytomX Therapeutics include Ajinomoto Althea, Ablynx and Moleculin Biotech.

  • Where is CytomX Therapeutics headquarters?

    CytomX Therapeutics headquarters is located at 151 Oyster Point Blvd #400, South San Francisco.

  • Where are CytomX Therapeutics offices?

    CytomX Therapeutics has an office in South San Francisco.

  • How many offices does CytomX Therapeutics have?

    CytomX Therapeutics has 1 office.